Yesterday's news seems to indicate that CRMD has a plan. Hopefully they move up a tranche in the next financing round. A good hedge fund could bring more than $$$$$ to the table.
This will be all about execution. Beyond the Tauropharm issue CRMD will need to convince German(Euro) healthcare system of cost/benefit advantage of moving from older catheter lock products to Neutrolin. The good news is tthat the Europeans tend to look at total cost of care so infection prevention will be a major plus.
IP issue is the wildcard. Any settlement or eventual legal victory changes the timeline here re: robust sales dramatically.